Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid

Hiroyuki Fujita, Aya Nakaya, Jun Kato, Takayoshi Tachibana, Sachiya Takemura, Rie Hyo, Tomoko Kawano, Masatsugu Tanaka, Jun Taguchi, Atsuo Maruta, Katsumichi Fujimaki, Heiwa Kanamori, Yoshiaki Ishigatsubo

Research output: Contribution to journalArticle

Abstract

Despite the use of all-trans retinoic acid (ATRA) as the first-line treatment for acute promyelocytic leukemia (APL), relapse occurs in about 20% of cases. Most relapsing APL patients can achieve second remission (CR2) following ATRA combined with chemotherapy or arsenic trioxide. Stem cell transplantation (SCT) has been widely adopted in CR2, but optimal SCT (auto- or allo-SCT) remains controversial. We analyzed the outcomes for 8 APL patients initially treated using ATRA, who relapsed, achieved CR2 and underwent auto-SCT (n = 4) or allo-SCT (n = 4). The mean age of patients who underwent allo-SCT was 39 years. Minimal residual disease (MRD) just prior to SCT was positive in 1 patient and negative in 3. Engraftment was achieved in all patients, but 2 patients died of transplantation-related complications within 6 months. Complete molecular remission has been maintained in the remaining 2 patients. The mean age of patients who underwent auto-SCT was 48 years. MRD just prior to SCT was negative in all 4 patients. Complete molecular remission has been maintained in all 4 patients (mean follow-up, 3 years 9 months). The results for auto-SCT are favorable in patients with MRD-negative APL.

Original languageEnglish
Pages (from-to)1095-1099
Number of pages5
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume46
Issue number10
Publication statusPublished - 2005
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Hematopoietic Stem Cell Transplantation
Tretinoin
Stem Cell Transplantation
Residual Neoplasm
Transplantation

Cite this

Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid. / Fujita, Hiroyuki; Nakaya, Aya; Kato, Jun; Tachibana, Takayoshi; Takemura, Sachiya; Hyo, Rie; Kawano, Tomoko; Tanaka, Masatsugu; Taguchi, Jun; Maruta, Atsuo; Fujimaki, Katsumichi; Kanamori, Heiwa; Ishigatsubo, Yoshiaki.

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 46, No. 10, 2005, p. 1095-1099.

Research output: Contribution to journalArticle

Fujita, H, Nakaya, A, Kato, J, Tachibana, T, Takemura, S, Hyo, R, Kawano, T, Tanaka, M, Taguchi, J, Maruta, A, Fujimaki, K, Kanamori, H & Ishigatsubo, Y 2005, 'Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid', [Rinshō ketsueki] The Japanese journal of clinical hematology, vol. 46, no. 10, pp. 1095-1099.
Fujita, Hiroyuki ; Nakaya, Aya ; Kato, Jun ; Tachibana, Takayoshi ; Takemura, Sachiya ; Hyo, Rie ; Kawano, Tomoko ; Tanaka, Masatsugu ; Taguchi, Jun ; Maruta, Atsuo ; Fujimaki, Katsumichi ; Kanamori, Heiwa ; Ishigatsubo, Yoshiaki. / Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid. In: [Rinshō ketsueki] The Japanese journal of clinical hematology. 2005 ; Vol. 46, No. 10. pp. 1095-1099.
@article{e48a8e8b3c134c2989b1e9b33688fdc2,
title = "Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid",
abstract = "Despite the use of all-trans retinoic acid (ATRA) as the first-line treatment for acute promyelocytic leukemia (APL), relapse occurs in about 20{\%} of cases. Most relapsing APL patients can achieve second remission (CR2) following ATRA combined with chemotherapy or arsenic trioxide. Stem cell transplantation (SCT) has been widely adopted in CR2, but optimal SCT (auto- or allo-SCT) remains controversial. We analyzed the outcomes for 8 APL patients initially treated using ATRA, who relapsed, achieved CR2 and underwent auto-SCT (n = 4) or allo-SCT (n = 4). The mean age of patients who underwent allo-SCT was 39 years. Minimal residual disease (MRD) just prior to SCT was positive in 1 patient and negative in 3. Engraftment was achieved in all patients, but 2 patients died of transplantation-related complications within 6 months. Complete molecular remission has been maintained in the remaining 2 patients. The mean age of patients who underwent auto-SCT was 48 years. MRD just prior to SCT was negative in all 4 patients. Complete molecular remission has been maintained in all 4 patients (mean follow-up, 3 years 9 months). The results for auto-SCT are favorable in patients with MRD-negative APL.",
author = "Hiroyuki Fujita and Aya Nakaya and Jun Kato and Takayoshi Tachibana and Sachiya Takemura and Rie Hyo and Tomoko Kawano and Masatsugu Tanaka and Jun Taguchi and Atsuo Maruta and Katsumichi Fujimaki and Heiwa Kanamori and Yoshiaki Ishigatsubo",
year = "2005",
language = "English",
volume = "46",
pages = "1095--1099",
journal = "[Rinshō ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "10",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid

AU - Fujita, Hiroyuki

AU - Nakaya, Aya

AU - Kato, Jun

AU - Tachibana, Takayoshi

AU - Takemura, Sachiya

AU - Hyo, Rie

AU - Kawano, Tomoko

AU - Tanaka, Masatsugu

AU - Taguchi, Jun

AU - Maruta, Atsuo

AU - Fujimaki, Katsumichi

AU - Kanamori, Heiwa

AU - Ishigatsubo, Yoshiaki

PY - 2005

Y1 - 2005

N2 - Despite the use of all-trans retinoic acid (ATRA) as the first-line treatment for acute promyelocytic leukemia (APL), relapse occurs in about 20% of cases. Most relapsing APL patients can achieve second remission (CR2) following ATRA combined with chemotherapy or arsenic trioxide. Stem cell transplantation (SCT) has been widely adopted in CR2, but optimal SCT (auto- or allo-SCT) remains controversial. We analyzed the outcomes for 8 APL patients initially treated using ATRA, who relapsed, achieved CR2 and underwent auto-SCT (n = 4) or allo-SCT (n = 4). The mean age of patients who underwent allo-SCT was 39 years. Minimal residual disease (MRD) just prior to SCT was positive in 1 patient and negative in 3. Engraftment was achieved in all patients, but 2 patients died of transplantation-related complications within 6 months. Complete molecular remission has been maintained in the remaining 2 patients. The mean age of patients who underwent auto-SCT was 48 years. MRD just prior to SCT was negative in all 4 patients. Complete molecular remission has been maintained in all 4 patients (mean follow-up, 3 years 9 months). The results for auto-SCT are favorable in patients with MRD-negative APL.

AB - Despite the use of all-trans retinoic acid (ATRA) as the first-line treatment for acute promyelocytic leukemia (APL), relapse occurs in about 20% of cases. Most relapsing APL patients can achieve second remission (CR2) following ATRA combined with chemotherapy or arsenic trioxide. Stem cell transplantation (SCT) has been widely adopted in CR2, but optimal SCT (auto- or allo-SCT) remains controversial. We analyzed the outcomes for 8 APL patients initially treated using ATRA, who relapsed, achieved CR2 and underwent auto-SCT (n = 4) or allo-SCT (n = 4). The mean age of patients who underwent allo-SCT was 39 years. Minimal residual disease (MRD) just prior to SCT was positive in 1 patient and negative in 3. Engraftment was achieved in all patients, but 2 patients died of transplantation-related complications within 6 months. Complete molecular remission has been maintained in the remaining 2 patients. The mean age of patients who underwent auto-SCT was 48 years. MRD just prior to SCT was negative in all 4 patients. Complete molecular remission has been maintained in all 4 patients (mean follow-up, 3 years 9 months). The results for auto-SCT are favorable in patients with MRD-negative APL.

UR - http://www.scopus.com/inward/record.url?scp=33644886338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644886338&partnerID=8YFLogxK

M3 - Article

C2 - 16440769

AN - SCOPUS:33644886338

VL - 46

SP - 1095

EP - 1099

JO - [Rinshō ketsueki] The Japanese journal of clinical hematology

JF - [Rinshō ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 10

ER -